Southdakota Chronicle

Delveinsight Business Research LLP

The key players in the Adrenoleukodystrophy therapeutics market include Bluebird Bio, Minoryx Therapeutics and Magenta Therapeutics, and others. Of the emerging therapies, the most anticipated products to get approved in upcoming years are Lenti-D (Gene therapy; Bluebird Bio), Leriglitazone (MIN-102) (Minoryx Therapeutics), and MGTA-456 (Magenta Therapeutics).

DelveInsight’s “Adrenoleukodystrophy (ALD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adrenoleukodystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Adrenoleukodystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Adrenoleukodystrophy (ALD): An Overview

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, which leads to the development of seizures and hyperactivity.

The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may also be clinically affected. There are three basic forms of ALD: neonatal, childhood, and adult-onset. Childhood ALD is the classical and the most severe form, leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome).

Adrenoleukodystrophy (ALD) Market Key Facts

• In 2021, the total prevalent population of ALD in the 7MM was 56,200+.

• It is estimated that in 2021, the prevalent population of ALD in the US was 19,900+. A higher percentage of prevalence was observed for females, in comparison to males, in the US. 

• In 2021, among the EU5, Germany had the highest prevalent population of ALD with 7,100+ cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest prevalent population of ALD, with 4,400+ cases in 2021.

• Based on the type of ALD, we have assessed that the majority of the patients suffer from Cerebral ALD, with 1,300+ cases observed in the US in 2021, while AMN and Addison Disease account for nearly 932, and 378 cases of the total diagnosed male symptomatic ALD population.

Adrenoleukodystrophy (ALD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Adrenoleukodystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Adrenoleukodystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Adrenoleukodystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Adrenoleukodystrophy Epidemiology, Segmented as –

• Total Prevalent Population of ALD in the 7MM [2019–2032]

• Gender-specific Prevalence of ALD in the 7MM [2019–2032]

• Gender-specific Diagnosed Prevalent Population of ALD in the 7MM [2019–2032]

• Type-specific Diagnosed Prevalence of ALD in males in the 7MM [2019–2032]

Adrenoleukodystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Adrenoleukodystrophy market or expected to be launched during the study period. The analysis covers the Adrenoleukodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adrenoleukodystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Adrenoleukodystrophy Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Adrenoleukodystrophy (ALD) Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Adrenoleukodystrophy (ALD). Currently, bluebird bio is leading the therapeutics market with its Adrenoleukodystrophy (ALD) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Adrenoleukodystrophy (ALD) Therapeutics Market Include:

• bluebird bio

• Applied Genetic Technologies Corporation

• Poxel

• Minoryx Therapeutics

• Orpheris

• MedDay Pharmaceuticals

• Viking Therapeutics

• bluebird bio

• Minoryx Therapeutics, S.L.

• MedDay Pharmaceuticals

• Magenta Therapeutics

• Orpheris Inc.

• SOM Biotech

And Many Others

Adrenoleukodystrophy (ALD) Emerging and Marketed Drugs Covered in the Report Include:

• Elivaldogene autotemcel: bluebird bio

• Leriglitazone: Minoryx Therapeutics

• OP 101: Ashvattha Therapeutics

• MGTA-456: Magenta Therapeutics, Inc.

• VK 0214: Viking Therapeutics

• Adrenoleukodystrophy gene therapy (Research Programme) – AGTC

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Adrenoleukodystrophy Competitive Intelligence Analysis

4. Adrenoleukodystrophy Market Overview at a Glance

5. Adrenoleukodystrophy Disease Background and Overview

6. Adrenoleukodystrophy Patient Journey

7. Adrenoleukodystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Adrenoleukodystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Adrenoleukodystrophy Unmet Needs

10. Key Endpoints of Adrenoleukodystrophy Treatment

11. Adrenoleukodystrophy Marketed Products

12. Adrenoleukodystrophy Emerging Drugs and Latest Therapeutic Advances

13. Adrenoleukodystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Adrenoleukodystrophy Market Outlook (In US, EU5, and Japan)

16. Adrenoleukodystrophy Access and Reimbursement Overview

17. KOL Views on the Adrenoleukodystrophy Market

18. Adrenoleukodystrophy Market Drivers

19. Adrenoleukodystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/